Evidence map›Paper›PMID 42828737›Full record

ArticleDrug delivery2026

Oral delivery of recombinant

Eliska Kopecna, Leona Raskova Kafkova, Petr Kosztyu, Kristyna Sloupenska, Katerina Zachova, Alica Cutkova, Jozef Skarda, Jana Vaculova, Milan Kuchar, Natalya Panova and 5 more

Abstract read
In one paragraph

Article in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Eliska KopecnaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Leona Raskova KafkovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.ORCID 0000-0002-2016-1886
Petr KosztyuDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Kristyna SloupenskaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Katerina ZachovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Alica CutkovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Jozef SkardaInstitute of Clinical and Molecular Pathology and Medical Genetics, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Jana VaculovaInstitute of Clinical and Molecular Pathology and Medical Genetics, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Milan KucharLaboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Vestec, Czech Republic.
Natalya PanovaLaboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Vestec, Czech Republic.
Stephen WalimbwaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
Tina Vida PlavecDepartment of Biotechnology, Jozef Stefan Institute, Ljubljana, Slovenia.
Ales BerlecDepartment of Biotechnology, Jozef Stefan Institute, Ljubljana, Slovenia.
Petr MalyLaboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Vestec, Czech Republic.
Milan RaskaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.ORCID 0000-0002-8572-7246

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin 23 (IL-23) is a key mediator of immune-mediated intestinal inflammation and plays an important role in the pathogenesis of inflammatory bowel disease. Inhibition of IL-23 signaling has therefore been validated as a therapeutic target in IBD. Here, we tested small binding proteins of non-immunoglobulin origin targeting either the IL-23 cytokine p19 subunit or the IL-23 receptor subunit IL-23R, designated ILP and REX binders, respectively. ILP317 and REX115 variants of formerly identified protein collections were tested in murine experimental colitis.

Indexed as

ColitisInterleukin-23Lactococcus lactisAdministration, OralAnimalsColonCytokinesDextran SulfateDisease Models, AnimalMaleMiceMice, Inbred C57BLRecombinant ProteinsTrinitrobenzenesulfonic AcidCytokinesDextran SulfateInterleukin-23Recombinant ProteinsTrinitrobenzenesulfonic Acidexperimental colitisIL-23oral therapyrecombinant Lactococcus lactissmall binding protein

Identifiers

PMID42828737
PMCPMC13644427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.